Literature DB >> 19653880

Therapeutic applications of DNA and RNA aptamers.

Kristina W Thiel1, Paloma H Giangrande.   

Abstract

Structured single-stranded nucleic acids, or aptamers, bind target molecules with high affinity and specificity, which translates into unique therapeutic possibilities. Currently, aptamers can be identified to most proteins, including blood-clotting factors, cell-surface receptors, and transcription factors. Chemical modifications to the oligonucleotides enhance their pharmacokinetics and pharmacodynamics, thus extending their therapeutic potential. Several aptamers have entered the clinical pipeline for applications and diseases such as macular degeneration, coronary artery bypass graft surgery, and various types of cancer. Furthermore, the functional repertoire of aptamers has expanded with the descriptions of multivalent agonistic aptamers and aptamers-siRNA chimeras. This review highlights those aptamers and aptamer-based approaches with particular likelihood of achieving therapeutic application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653880      PMCID: PMC6469516          DOI: 10.1089/oli.2009.0199

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  67 in total

Review 1.  RNA-based therapeutics: current progress and future prospects.

Authors:  John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2012-01-27

Review 2.  Cell-specific aptamer-mediated targeted drug delivery.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Oligonucleotides       Date:  2010-12-23

Review 3.  Tumor-targeted drug delivery with aptamers.

Authors:  Y Zhang; H Hong; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.

Authors:  William H Thiel; Carla L Esposito; David D Dickey; Justin P Dassie; Matthew E Long; Joshua Adam; Jennifer Streeter; Brandon Schickling; Maysam Takapoo; Katie S Flenker; Julia Klesney-Tait; Vittorio de Franciscis; Francis J Miller; Paloma H Giangrande
Journal:  Mol Ther       Date:  2016-01-06       Impact factor: 11.454

6.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Authors:  William M Rockey; Frank J Hernandez; Sheng-You Huang; Song Cao; Craig A Howell; Gregory S Thomas; Xiu Ying Liu; Natalia Lapteva; David M Spencer; James O McNamara; Xiaoqin Zou; Shi-Jie Chen; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-10       Impact factor: 5.486

Review 7.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

8.  Near-infrared light-responsive core-shell nanogels for targeted drug delivery.

Authors:  Huaizhi Kang; Anna Carolina Trondoli; Guizhi Zhu; Yan Chen; Ya-Jen Chang; Haipeng Liu; Yu-Fen Huang; Xiaoling Zhang; Weihong Tan
Journal:  ACS Nano       Date:  2011-05-17       Impact factor: 15.881

9.  Nucleotide bias observed with a short SELEX RNA aptamer library.

Authors:  William H Thiel; Thomas Bair; Kristina Wyatt Thiel; Justin P Dassie; William M Rockey; Craig A Howell; Xiuying Y Liu; Adam J Dupuy; Lingyan Huang; Richard Owczarzy; Mark A Behlke; James O McNamara; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-06-28       Impact factor: 5.486

10.  Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.

Authors:  William M Rockey; Ling Huang; Kyle C Kloepping; Nicholas J Baumhover; Paloma H Giangrande; Michael K Schultz
Journal:  Bioorg Med Chem       Date:  2011-05-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.